Viaskin Peanut: Completed Ph III REALISE enrollment

DBV completed enrollment of 394 patients ages 4-11 in the double-blind, placebo-controlled, North American Phase III REALISE trial evaluating once-daily 250 μg Viaskin Peanut for 6 months. Patients ar...